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Background. Cutaneous drug reactions are common but diagnostically challenging due to phenotypic heterogeneity and
simultaneous exposure to multiple drugs. These limitations prompted the development of diagnostic tests. Aims.T oe v a l u a t et h e
performanceofaninvitroassaymeasuringinterferon-gammareleasefrompatients’lymphocytesinthepresenceofcausativedrugs
for the diagnosis of drug reactions. Methods. Mononuclear cells derived from patients were incubated with and without suspected
drugs, and increment of interferon-gamma levels was measured by ELISA. We performed a telephonic survey to evaluate the eﬀect
of stopping the drugs incriminated by the assay on cutaneous manifestations. Results. We assessed 272 patients who used 1035
medications. When assessed against the questionnaire data collected at least 6 months after stopping the causative drug, sensitivity
was found to be 83.61% and speciﬁcity 92.67%. Likelihood ratio for a positive test is 11.40 and for a negative test 0.18. Positive
predictivevalueis75.37%andnegativepredictivevalueis95.47%.Thetestwasfoundtoperformsigniﬁcantlybetterinfemalesand
in older patients. Conclusions. Interferon-gamma release test is a useful adjunct tool in the diagnosis of cutaneous drug reactions.
1.Introduction
Cutaneous adverse drug reaction is a common phenomenon
consisting of pathological alterations of the structure and/or
the function of the skin, adnexa, and mucosa, as a result of
exposure to a medication. The plethora of clinical manifesta-
tions associated with cutaneous drug reactions signiﬁcantly
complicates clinical diagnosis as well as pharmacological
counseling. Indeed, many types of skin reactions to drugs
have been reported and many skin reactions may imitate
common diseases such as bullous diseases, psoriasis and
so forth [1–3]. In addition, very often patients with skin
drug reactions have been exposed to multiple drugs and
reactions to some drugs are characterized by a prolonged
latency period between exposure and the onset of the skin
reaction. Finally, numerous cofactors (such as viral infec-
tion or autoimmunity) are inﬂuencing the propensity to
develop allergic rashes to a given medication. To further
complicate the matter, associated laboratory ﬁndings such
as eosinophilia and liver function test abnormalities are
nonspeciﬁc and therefore unhelpful [4].
Thesefactshavepromptedthedevelopmentofnumerous
speciﬁc ancillary assays to assist physicians in the diagnosis
and prevention of drug reactions [4].
In vivo testing consisting in drug rechallenge entails ex-
posure of the patients to potentially harmful consequences
of the test and has been largely abandoned [4, 5]. Although
in vitro tests are generally technically more cumbersome,
they are being increasingly used because of safety consid-
erations and because they can be more easily standardized.
Many techniques have been developed which measure var-
ious immunological parameters in response to exposure of
patients’ cells to suspected drugs. These assays include radio-
allergosorbent tests (RAST) [6], mast cell degranulation test
[7], lymphocytic transformation test or proliferation test [8–
11], the release of beta glucuronidase from white cells test
[12], lymphocyte toxicity assay [13], macrophage migration
inhibitoryfactor(MIF)assay[14,15],andteststhatarebased2 Clinical and Developmental Immunology
on interferon-gamma (IFN-gamma) release from lympho-
cytes [5, 16–20].
A large body of in vivo and in vitro evidence indicates
that T lymphocytes are involved in the pathogenesis of cuta-
neous drug hypersensitivity. Drugs can stimulate subpopula-
tions of CD4 and CD8 type T cells [21]. These activated cells
secrete diﬀerent cytokines such as IFN-gamma [16]. Labo-
ratory tests that are based on the release of cytokines from
patient’s lymphocytes, in response to in vitro incubation
with the suspected drugs, may indicate a cellular immune
responseuniqueforthedrugandindicatetheroleofthedrug
incausingthereaction.IFN-gammaisTh1typecytokineand
is an important mediator of the delayed hypersensitivity that
acts also as a macrophage activator. In vitro demonstration
of IFN-gamma release from lymphocytes after an in vitro
incubation with a suspected drug has been shown to be
of diagnostic value in skin reactions based on the demon-
stration of cutaneous rash resolution upon cessation of the
drug incriminated by the in vitro assay [5]. Unfortunately,
much of the data supporting the use of in vitro assay to
diagnose cutaneous drug reactions are based on short-term
followup of the patients. The aim of the present study was
to determine the performance of the IFN-gamma release
assay when assessed against the data of long-term patients
followup.
2. Methods
2.1. Study Population. The study was approved by the Med-
ical Center Ethics Committee. We assessed all patients with
cutaneous adverse drug reactions who underwent a routine
IFN-gamma release testing at our department between the
years 2003–2007.
Clinical data were collected from the patient’s medical
ﬁles and from a telephonic interview with the patient. The
details collected included demographic data (age, sex), type
of skin reaction, suspected drug, whether the treatment with
the drug was stopped following the test, whether there was
an improvement in the state of the rash, whether the rash
relapsed, was there an event that preceded the relapse of the
rash,whetheradiﬀerentdiagnosiswasfoundfortherashand
was it treated.
Clinical improvement attributable to drug cessation was
deﬁned when the patient reported one of the following:
(a) Improvement of the rash without relapse, upon ces-
sation of the drug.
(b) Improvement of the rash upon cessation of the drug
and relapse of the rash as the patient renewed the
drug.
(c) Improvement of the rash upon cessation of the drug
and relapse of the rash as the patient started taking a
drugstructurallyrelatedtothedrugthatwasstopped.
Absence of clinical improvement attributable to drug cessa-
tionwasdeﬁnedwhenthepatientreportedoneofthefollow-
ing:
(a) There was no clinical improvement of the rash after
the patient stopped using the drug.
(b) There was improvement in the rash although the
patient continued using the suspected drug.
(c) Therewasimprovementintherashuponcessationof
the drug and relapse of the rash although the patient
did not renew the drug.
(d) Clinical improvement followed another diagnosis
and a speciﬁc treatment for that diagnosis.
Basedonthesedata,wedividedourpopulationinto4groups
(Figure 1):
Group A: true positive,
Group B: false positive,
Group C: true negative,
Group D: false negative.
We also divided our population into 5 groups according to
the type of the rash:
Group 1: patients with urticaria,
Group 2: patients with morbilliform rash,
Group 3: patients with psoriasis/psoriasiform eruption,
Group 4: patients with vasculitis,
Group 5: patients with other skin reactions.
2.2. IFN-Gamma Release Test. Lymphocytes were separated
from heparinized venous blood by Ficoll-Hypaque gradient
centrifugation and cultured for 24 hours in 24 well plates
containing Dulbecco’s Modiﬁed Eagle’s medium (Biological
industries, Beit Haemek, Israel), phytohemagglutinin (Bio-
logical industries, Beit Haemek, Israel), in the presence and
theabsenceofthedrug.Followingincubationfor24hoursin
5% CO2 at 37◦C and centrifugation at 2500rpm for 25min
at 5◦C, the supernatants were collected for the detection of
IFN-gamma using a standard ELISA assay (Biosource, Enco
Diagnostics, Petach Tikvah, Israel). IFN-gamma release was
expressed as follows: 100 × (IFN-gamma with the drug −
IFN-gammawithmediumalone)/IFN-gammawithmedium
alone.
A positive test was deﬁned as corresponding to a value
of more than 130%. A borderline test was deﬁned as a value
between 120%–129% [4].
2.3. Statistical Methods. Calculation of sensitivity, speciﬁcity,
likelihood ratio, and 95% conﬁdence intervals was made
using a standard statistical program (WINPEPI for Win-
dows) [22].
Evaluation of odds ratio (OR) and conﬁdence intervals
for clinical improvement according to drugs usage and the
test’s results was made using logistic regression model with
adjustments to age and sex (SPSS for Windows).
3. Results
284 patients were assessed in this study. In 12 (4.25%)
patients,wecouldnotretrieveallinformationdataduetothe
death of the patient or lack of patient’s ability to answer our
questions. Thus, all subsequent calculations were obtained
using the set of 272 remaining patients. Altogether, these
patients were found to receive a total of 1035 medications
prior to the onset of the cutaneous rash. These medicationsClinical and Developmental Immunology 3
Patients with
positive test
Stopped the
suspected drug
Did not stop
the suspected drug
No clinical
improvement∗
Clinical
improvement
(false positive)
No clinical
improvement
(false positive)
Clinical
improvement
(true positive)
Patients with
negative test
Did not stop the
suspected drug
Stopped the
suspected drug
Clinical
improvement
No clinical
improvement
(true negative)
Clinical
improvement
(true negative)
No clinical
∗ improvement
Another
diagnosis was
not made
(false negative)
Another
diagnosis was
made and treated
(true negative)
Figure 1: Division of study population. ∗It cannot be determined whether continuing the suspected drug is indeed responsible for the
continuing clinical symptoms. ∗∗It cannot be determined whether the drug that was found negative in the test is indeed not responsible for
the clinical symptoms.
Table 1: Correlation between clinical course and IFN-gamma release results for all medications.
Assay results False result according to
questionnaire
True result according to
questionnaire Total medications
Negative 30 632 662
Positive 50 153 203
Total 80 785 865
included antibiotics (7%), analgesics (20%), angiotensin-
converting enzyme inhibitors (4%), statins (7%), and others.
Of all 1035 drugs assessed, a deﬁnite (positive or negative)
result for the IFN-gamma release test was obtained in 953
(92%). In 82 (7.9%) of the medications, the test result was
borderline (a borderline test was deﬁned as corresponding
to an IFN-gamma release value between 120%–129%). Data
wereprocessedafterexcluding105medicationsforwhichthe
test results were without attribution to a study group (med-
ications for which it was impossible to determine whether
the continuation of the suspected drug was responsible for
the continuation of the clinical symptoms or that it was
impossible to determine whether the drug testing negative
by the IFN-gamma release assay was indeed not responsible
for the cutaneous symptoms). Of the 930 medications left,
865 (93%) were associated with a deﬁnite IFN-gamma
release assay result (785 true positive/negative results and 80
false positive/negative results) for which it was possible to
compare clinical outcome to test result (Table 1).
Sixty-ﬁve (7%) of the drugs tested borderline in the assay
and were classiﬁed as either positive borderline (n = 20;
a borderline result in the assay with clinical evidence for
a causative role of the drug in the cutaneous reaction) or
negative borderline (n = 45; a borderline result in the assay
for which no correlation between the test result and the
clinical course was found).
The sensitivity and speciﬁcity were determined based on
thedeﬁniteresults;borderlineandnonclassiﬁableassayswere
excluded from the analysis.
Sensitivity and speciﬁcity of the assay were 83.61% (C.I.
95%: 77.56%−88.27%) and 92.67% (C.I. 95%: 90.46%–
94.39%), respectively. Likelihood ratio for a positive or a
negativetestwas11.40,(C.I.95%:8.67–15.01)and0.18,(C.I.
95%:0.13–0.25),respectively.Thepositivepredictivevalueof4 Clinical and Developmental Immunology
Table 2: Inﬂuence of patient age and sex on the performance of the IFN-gamma release test.
Number of medications taken by the patients P Odds ratio for true result (95% conﬁdence
intervals)
Sex (men versus women), M: 316 medications, W: 549 medications 0.027 0.585 (0.364–0.940)
Age (per year) 0.006 1.016 (1.004–1.028)
Table 3: Correlation between patient’s sex and IFN-gamma release results for all medications.
Sex Test result False result according to
questionnaire
True result according to
questionnaire Total drugs
Women
Negative 16 395 411
Positive 28 110 138
Total 44 505 549
Men
Negative 14 237 251
Positive 22 43 65
Total 36 280 316
Table 4: Correlation between patient’s age and IFN-gamma release results for all medications.
Age group (years) Test result False result according to
questionnaire
True result according to
questionnaire Total drugs
≤44
Negative 9 155 164
Positive 20 52 72
Total 29 207 236
45–64
Negative 14 181 195
Positive 17 44 61
Total 31 225 256
≥65
Negative 7 296 303
Positive 13 56 69
Total 20 352 372
Table 5: Correlation between vasculitis patients (group 4) in comparison to other patients and IFN-gamma release results for all
medications.
Rash Test result False result according to
questionnaire
True result according to
questionnaire Total drugs
Other groups
Negative 30 600 630
Positive 49 141 190
Total 79 741 820
Group 4
Negative 0 32 32
Positive 1 12 13
Total 1 44 45
the test is 75.37% (C.I. 95%: 69.95–80.09%) and its negative
predictive value is 95.47% (C.I. 95%: 93.83–96.69%).
Inﬂuence of age and sex on the performance of the IFN-
gammareleasetestwasassessedusing amultivariable logistic
regression model, in which the dependent variable is a true
or false result (Table 2).
As shown in Table 2, age was signiﬁcantly associated with
a true positive/negative result in the IFN-gamma release test.
Every additional year of age was associated with a 1.6%
increase in the probability of a true result. Similarly, female
sex was associated with a signiﬁcantly higher rate of true
positive/negative result (P = 0.027). Odds ratio of a true
result in men was 41.5% lower as compared with women.
Among patients who display vasculitis, the probability of
a true result was slightly (but not signiﬁcantly) (P = 0.08)
higher than for patients aﬀected by an urticarial rash. There
was no statistically signiﬁcant diﬀerence between the rash
groups.
The speciﬁc eﬀect of age, sex, and type of skin reaction
on test performance is presented in Tables 3, 4,a n d5,Clinical and Developmental Immunology 5
Table 6:SensitivityandspeciﬁcityoftheIFN-gammareleasetest,andpositiveandnegativelikelihoodratioaccordingtopatient’sagegroups,
sex, and type of rash.
Age group/sex Sensitivity (%)
95% CI (range)
Speciﬁcity (%)
95% CI (range)
Likelihood ratio for a positive test
95% CI (range)
Likelihood ratio for a negative test
95% CI (range)
≤44 years 85.25 (74.28–92.04) 88.57 (83.01–92.48) 7.46 (4.87–11.41) 0.17 (0.09–0.13)
45–64 years 75.86 (63.47–85.04) 91.71 (87.12–94.76) 9.15 (5.67–14.75) 0.26 (0.17–0.42)
≥65 years 88.89 (78.8–94.51) 95.79 (92.94–97.53) 21.3 (12.32–36.23) 0.12 (0.06–0.23)
Women 87.30 (80.37–92.03) 93.38 (90.6–95.38) 13.19 (9.16–18.98) 0.14 (0.09–0.22)
Men 75.44 (62.9–84.77) 91.51 (87.47–94.32) 8.88 (5.8–13.6) 0.27 (0.17–0.42)
Vasculitis 100 (75.75–100) 96.97 (84.68–99.46) 33.0 (4.79–37.7) 0.00
All other skin
reactions 82.46 (76.06–87.43) 92.45 (90.16–94.24) 10.9 (8.27–14.42) 0.19 (0.14–0.26)
respectively. The test’s sensitivity, speciﬁcity, and positive
and negative likelihood ratio derived from these data are
presented in Table 6.
4. Discussion
As discussed above, cutaneous drug reactions are often diag-
nostically very challenging. To our knowledge, the present
data provide, for the ﬁrst time, evidence based on long-term
follow-up data that an in vitro assay may represent a useful
adjunct to the clinical diagnosis of this common dermato-
logical occurrence. This is of particular importance when
the morphological features of the rash overlap with those
of a common drug-unrelated skin eruption (e.g., psoriasis).
In addition, when a patient is taking a number of drugs
simultaneously, in vitro ancillary assays can help pointing
out the culprit drug and avoid unnecessary withdrawal of
essential medications.
The IFN-gamma release assay is based on the involve-
ment of T lymphocytes in the pathogenesis of cutaneous
adverse drug reactions. Drugs stimulate subpopulation of
CD4+ and CD8+ type T cells, with Th1 or Th2 cytokines
pattern, according to the drug and the drug reaction type
[21]. Reactions associated with delayed hypersensitivity are
characterized by preferential activation of Th1 cells. In
contrast,drugeruptionsresultingfromimmediatehypersen-
sitivity are characterized by a Th2 reaction pattern. Interest-
ingly, although IFN-gamma is typically categorized as a Th1
cytokine, high levels of this molecule have been detected in
patients with immediate hypersensitivity reactions [23].
In this study, sensitivity, speciﬁcity, positive and negative
predictive values of an IFN-gamma release assay were found
to be high for the diagnosis of cutaneous skin reactions.
Previous studies have similarly examined the eﬃcacy of
this test and their results are in line with the present data.
However,thisstudyexaminedthereliabilityofthetestresults
over a long period of time as patients were interviewed at
least half a year after the test was performed, in order to ﬁnd
out if there was a relapse of the rash after the cessation of
the drug, or whether the patient continued to take the drugs
withoutarash,andthusknowingretrospectivelywhetherthe
test result was true or false.
65(7%)ofthedrugshadaborderlineresultinthetest(45
of them were retrospectively found to be clinically negative
and 20 clinically positive). Although most of the borderline
results were found to be clinically negative, it is still impor-
tant to deﬁne for this test a range of borderline results
(between 120%–130% increase in IFN-gamma release), in
ordernot tomiss casesin whichthe drugs are indeed respon-
sible for the skin reaction. In patients for whom all drugs
are tested negative and/or borderline, it is recommended to
avoid using the borderline drugs.
Livni et al. examined the eﬃcacy of the test in patients
with urticaria and angioedema. They found that the test’s
sensitivity was 50% and its speciﬁcity 92%. They also com-
pared the IFN-gamma release assay with the MIF assay and
found 80.9% agreement between the two tests [19]. In a
study that examined the test’s eﬃcacy in cases of allergy
to potassium dichromate in 20 allergic patients and 30
control individuals, the assay’s sensitivity was 73.7% and its
speciﬁcity 71.4% [24]. In another study of 36 patients with
cutaneous adverse drug reactions, the test was found to be
characterized by a sensitivity of 77.8% [16].
False positive results can result from many causes includ-
ing performance of the assay during the acute phase of the
rash, cross reactivity or multiple drug allergy syndrome or
sensitivity to a preservative that is found in a number
of drugs [16]. Non-IFN-related mechanisms may underlie
cutaneous drug reactions for which false negative results
are obtained. As mentioned above, there are skin reactions
caused by nonimmunological mechanisms or characterized
by cytokine release patterns that do not involve interferon
secretion [25]. Another reason for false negative results is
the fact that in some cases drug metabolites or haptenized
drugs rather than the native drug are responsible for the
pathological reaction [26–28]. Photosensitive reaction is
anotherexampleofadrugallergythatmaynotbereﬂectedin
an in vitro assay [29]. An additional reason for false negative
results is a test performed during a corticosteroid or other
immunosuppressive treatment.
It should be noted that, in this study, in most of the
patients for whom a drug that caused the rash was identiﬁed,
the other drugs that the patient used tested negative (even
if the patient used more than 10 drugs), underscoring the
usefulness of this assay in enabling continued administration
of important drugs.
In our study we found that the test performed signiﬁ-
cantly better in women than in men (P = 0.027). This is6 Clinical and Developmental Immunology
in agreement with another study, recently published by Saito
et al. which compared between the eﬃcacy of the leukocyte
migration test (LMT) and of the lymphocyte stimulation test
(LST) to assess drug sensitivity. In that study it was found
that women had signiﬁcantly more positive results than men
for the LMT assay, which may be related to the fact women
produce higher levels of cytokines and chemokines from
lymphocytes than men [30].
Our study also revealed that older people were more
likely to have true positive/negative results than younger
people. Saito et al. did not report signiﬁcant diﬀerence in the
results by age, although they mentioned such diﬀerences in
their previous study [30]. This ﬁnding is somewhat diﬃcult
to interpret and it may be related to the type of drugs that
theolderpopulation usesincomparisontoyoungerpatients,
and to the types of rash and their inﬂuence on the cytokine
pattern that is produced by the lymphocytes.
When we assessed the patients by the type of rash, we
found that patients with vasculitis showed a trend (P =
0.08) for higher sensitivity and speciﬁcity values (100% and
96.97% resp.), in comparison to patients in other groups
(Table 6). In another study that examined the performance
oftheIFN-gammareleasetest,ahighincreaseinIFN-gamma
releasewasfoundamongpatientswithvasculitis,andthetest
was found positive in 100% of patients with vasculitis [16].
In conclusion, in this study we examined the perfor-
mance of the IFN-gamma release test as assessed against data
collected from a large number of patients over a prolonged
periodoftime.Theresultsofthestudyindicatethatthisassay
can serve as a useful adjunct in the diagnosis of cutaneous
drug reactions.
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